

ALL IMAGES VIDEOS

56,500 Results Any time

[Increased cumulative doses and appearance of hand-foot ...](https://pubmed.ncbi.nlm.nih.gov/30063012)<https://pubmed.ncbi.nlm.nih.gov/30063012>

Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients Kaohsiung J Med Sci . 2018 Jul;34(7):391-399. doi: 10.1016/j.kjms.2018.03.006.

Cited by: 3 Author: Wen-Tsan Chang, Sheng-Nan Lu, Kung-...

Publish Year: 2018

Search Tools

[Turn off Hover Translation \(关闭翻译\)](#)[As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea ...](#)<https://pubmed.ncbi.nlm.nih.gov/31815114>

Background: Combination therapy of transarterial chemoembolization plus sorafenib (TACE-S) has been proven to be safe and effective for hepatocellular carcinoma (HCC); however, this combination therapy is associated with a high incidence of adverse events (AEs). Our study focused on the relationships between AEs and treatment outcomes and aimed to discover AE-based clinical markers that can ...

ALL IMAGES VIDEOS

56,500 Results Any time ▾

[Increased cumulative doses and appearance of hand-foot ...](https://pubmed.ncbi.nlm.nih.gov/30063012)<https://pubmed.ncbi.nlm.nih.gov/30063012>

Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients Kaohsiung J Med Sci . 2018 Jul;34(7):391-399. doi: 10.1016/j.kjms.2018.03.006.

Cited by: 3 Author: Wen-Tsan Chang, Sheng-Nan Lu, Kung-...

Publish Year: 2018

Search Tools

[Turn off Hover Translation \(关闭翻译\)](#)[As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea ...](#)<https://pubmed.ncbi.nlm.nih.gov/31815114>

Background: Combination therapy of transarterial chemoembolization plus sorafenib (TACE-S) has been proven to be safe and effective for hepatocellular carcinoma (HCC); however, this combination therapy is associated with a high incidence of adverse events (AEs). Our study focused on the relationships between AEs and treatment outcomes and aimed to discover AE-based clinical markers that can ...

06-Aug-2021 12:13PM

4014 words - 6 matches - 2 sources

66701_Auto_Edited.docx

Quoted Excluded
Bibliography Excluded

3%

100.00

iThenticate

Match Overview

1

Internet 55 words
Crawled on 13-Jul-2019
www.thieme-connect.com

1%

2

Crossref 40 words
Ami Rambhia, Rolf D Pelet, Kennedy E Okhaweme, Taka G K
om, Keshi N Odoani. "immunotherapy for metastatic renal cel

1%

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 66701

Manuscript Type: ORIGINAL ARTICLE

Retrospective Study

Prolonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment

Masanori Ochi, Toshiro Kamoshida, Masahiro Araki, Tadashi Ikegami

Abstract

BACKGROUND

PAGE: 1 OF 14

Test Only Report

国内版

国际版

Prolonged survival in patients with hand-foot skin reaction second



ALL

IMAGES

VIDEOS

12,500 Results

Any time ▾

Prevention of Hand-foot Skin Reaction - Full Text View ...

<https://clinicaltrials.gov/ct2/show/NCT04568330> ▾

Sep 29, 2020 · Chang WT, Lu SN, Rau KM, Huang CS, Lee KT. Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients. Kaohsiung J Med Sci. 2018 Jul;34(7):391-399. doi: 10.1016/j.kjms.2018.03.006. Epub 2018 Apr 4.

Actual Enrollment : 129 participants

Allocation: Randomized

Intervention Model: Parallel Assignment

Study Type : Interventional (Clinical Trial)

Increased cumulative doses and appearance of hand-foot ...

<https://www.sciencedirect.com/science/article/pii/S1607551X1730832X>

Jul 01, 2018 · Patients with (A) total dosages>55000 mg (B) daily dosages<562 mg (C) dosage durations>112 day, and (D) hand-foot skin reactions had significantly longer median progression-free survival (PFS) (E) The presence of diarrhea did not predict prolonged PFS.

Cited by: 4

Author: Wen-Tsan Chang, Sheng-Nan Lu, Kung-...

Publish Year: 2018

Complete response: 0 (0%)

Hand-foot syndrome and survival in patients with advanced ...

<https://link.springer.com/article/10.1007/s10147-020-01683-0> ▾

May 24, 2020 · Several studies have found that patients receiving sorafenib therapy with HFS exhibit good OS in advanced hepatocellular carcinoma [10, 11]. In the ALTER 0303 study, the median time of HFS in the anlotinib group was 30 days (range of 24–41 days) [12].

Author: Xueli Nan, Chao Xie, Qingqing Zhu, Jia...

Publish Year: 2020

Estimated Reading Time: 10 mins

Hand-foot-skin reaction of grade ≥ 2 within sixty days as ...

<https://link.springer.com/article/10.1007/s10637-018-0640-7> ▾

Jul 18, 2018 · Sorafenib is a commonly used systemic therapy for patients with hepatocellular carcinoma (HCC) and one of the first-line treatment option for advanced-stage disease, according to the American Association for the Study of Liver Diseases/Barcelona Clinic of Liver Cancer (AASLD/BCLC) staging system and treatment guidelines [1,2,3]. To date, unlike malignances of the breast [], lung [] and

...